Alkermes ALKS
NASDAQ ALKS
$46.17 +0.27 (+0.59%)
At close: Nov 9, 2026 · 4:00 PM EST

Alkermes (ALKS) Gains from Sales and Divestitures (2014 - 2015)

Updated

Analysis

Alkermes (ALKS) Gains from Sales and Divestitures (2014 - 2015) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Alkermes 7.77 Bn 5.26 Bn 385.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 -301,000.00
Sep 30, 2015 26,000.00
Jun 30, 2015 9.91 Mn
Dec 31, 2014 28.16 Mn
Sep 30, 2014 -218,000.00
API Access

Alkermes Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ALKS&period=max&api_key=YOUR_API_KEY